Latest News & Updates

Breaking News

  • 9 hours ago

  • Simantini Singh Deo

Beacon Therapeutics Begins LANDSCAPE Trial With First Patient Dosed In laru-zova Study For X-Linked Retinitis Pigmentosa
Breaking News
Cellectar Biosciences Signs Strategic Supply Agreement With Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapy Development

Simantini Singh Deo

Other trending news you may like to read

Beacon Therapeutics Begins LANDSCAPE Trial With First Patient Dosed In laru-zova Study For X-Linked Retinitis Pigmentosa

Beacon Therapeutics treats first patient in LANDSCAPE trial evaluating bilateral laru-zova gene therapy for X-linked retinitis pigmentosa.

Simantini Singh Deo

Pharma Now

Cellectar Biosciences Signs Strategic Supply Agreement With Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapy Development

Cellectar Biosciences signs multi-year deal with Ionetix for Ac-225 and At-211 supply to support targeted alpha therapy programs.

Simantini Singh Deo

Pharma Now

Recludix Pharma Receives FDA Clearance for Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Begin Clinical Trials

Recludix Pharma gets FDA clearance for Phase 1 trial of REX-8756, an oral STAT6 inhibitor for treating inflammatory diseases.

Simantini Singh Deo

Pharma Now

PolyPid Appoints Experienced MedTech Executive Brooke Story As Chairman Of Its Board Of Directors

PolyPid appoints Brooke Story as Board Chair to guide growth and commercialization of its surgical infection prevention programs.

Simantini Singh Deo

Pharma Now